A Phase I trial in 39 healthy adults tests a universal SARS-like coronavirus vaccine developed by the University of Cambridge and DIOSynVax, using an AI-designed conserved “super-antigen” to induce immunity across related viruses.

The AI-designed vaccine targets a common, essential part of Sarbecoviruses rather than individual strains, aiming for broad protection against entire virus families and potential future mutations.

The approach leverages global genetic sequence data to identify conserved viral features that are hard for viruses to escape, with the goal of broad and durable immunity.

Results were published in the Journal of Infection, led by Professor Jonathan Heeney, and supported by NIHR infrastructure and Innovate UK funding.

The platform could be adaptable to other viral families, such as Influenza and Ebola, signaling a proactive, future-proof approach to pandemic threats.

Proponents argue the technology could save lives and reduce lockdowns and economic disruption, though further development and larger trials are needed.

Innovate UK funding supports DIOSynVax’s broader pipeline, which includes vaccines for seasonal influenza and hemorrhagic fevers.

Initial human data showed only a modest immune response, but the work is described as a fundamental shift in pandemic preparedness with potential to outpace mutations.

If later phases prove successful, the approach could transform vaccine development from reactive updates to proactive, broad protection against viral families.

The program envisions protection across thousands of variants and viruses, including Ebola, potentially preventing outbreaks before they start.

Experts view this as a paradigm shift from reactive vaccines to preemptive, broad multi-variant protection that could reduce pandemic risk and lockdowns.

Researchers describe vaccines that target essential viral features as future-proofed and capable of offering protection beyond currently emerged viruses.